Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Review uri icon

Overview

MeSH Major

  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Hypertension
  • Hypertrophy, Left Ventricular
  • Losartan
  • Platelet Aggregation Inhibitors
  • Stroke

abstract

  • Sub-analyses of the LIFE study data suggest that losartan's stroke benefit may arise from a mosaic of mechanisms rather than a single action. Further studies are expected to continue to delineate the mechanisms of differential responses to treatments in LIFE.

publication date

  • February 2007

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1185/030079906X167435

PubMed ID

  • 17288698

Additional Document Info

start page

  • 443

end page

  • 57

volume

  • 23

number

  • 2